Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
1 study found for:    lymphoma [CONDITION] OR CLL [CONDITION] | Open Studies | tru-016
Show Display Options
Rank Status Study
1 Recruiting Phase 1b Safety and Efficacy Study of TRU-016 and Rituximab, Obinutuzumab, Idelalisib, or Ibrutinib in Chronic Lymphocytic Leukemia
Condition: Chronic Lymphocytic Leukemia
Interventions: Biological: 20 mg/kg TRU-016 + Rituximab;   Biological: 10 mg/kg TRU-016 + Rituximab;   Biological: TRU-016 20 mg/kg + Obinutuzumab;   Biological: TRU-016 6-20 mg/kg + idelalisib + rituximab;   Biological: TRU-016 10-20 mg/kg + ibrutinib

Study has passed its completion date and status has not been verified in more than two years.